WO2007042885A2 - Combinaison therapeutique - Google Patents

Combinaison therapeutique Download PDF

Info

Publication number
WO2007042885A2
WO2007042885A2 PCT/IB2006/002745 IB2006002745W WO2007042885A2 WO 2007042885 A2 WO2007042885 A2 WO 2007042885A2 IB 2006002745 W IB2006002745 W IB 2006002745W WO 2007042885 A2 WO2007042885 A2 WO 2007042885A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
methotrexate
amount
patient
day
Prior art date
Application number
PCT/IB2006/002745
Other languages
English (en)
Other versions
WO2007042885A3 (fr
Inventor
Craig Mason Flory
Wayne Daniel Klohs
Mark Bradley Meyer
Bernhardt George Zeiher
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of WO2007042885A2 publication Critical patent/WO2007042885A2/fr
Publication of WO2007042885A3 publication Critical patent/WO2007042885A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention generally relates to a therapeutic combination of compounds and the use of the combination to treat rheumatoid arthritis.
  • the RAF-MEK-ERK pathway mediates immunomodulation, inflammation, and proliferative and anti-apoptotic signaling from growth factors and oncogenic factors such as Ras and Raf mutant phenotypes.
  • Mitogen-activated protein kinase (MAPK) and extracellular regulated kinase (ERK, e.g., ERK-j and ERK2) are enzymes involved in controlling certain cellular processes.
  • Each MAPK consists of a series of three cytoplasmic kinases: a MAPK, a mitogen-activated protein kinase kinase (MAPKK), and a mitogen-activated protein kinase kinase kinase (MAPKKK).
  • MAPK/ERK Kinase (MEK) enzymes are dual specificity kinases that activate ERK.
  • MEK enzymes e;g.; MEK-
  • MEK enzymes are involved in, for example, rheumatoid arthritis, cancer, and restenosis.
  • An aspect of the present invention is a method of treating rheumatoid arthritis in a patient, the method comprising administering to a patient in need of rheumatoid arthritis treatment a therapeutically effective amount of a combination, consisting essentially of a first amount of N-[4-[[(2,4-diamino-6- pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid, or a pharmaceutically acceptable salt thereof, or a mixture thereof, and a second amount of N-[(R)-2,3- dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.
  • the method wherein the patient is a human and the first amount is from 1 mg to 30 mg and the second amount is from 1 mg to 30 mg. More preferred is any one of the above aspects of the method, wherein the patient is a human and the N-[4- [[(2,4-diamino-6-pteridinyi)methyl]methylamino]benzoyl]-L-glutamic acid, or the pharmaceutically acceptable salt thereof, is sodium N-[4-[[(2,4-diamino-6- pteridinyl)methyl]methylamino]benzoyl]-L-glutamate and the first amount is from 1 mg to 20 mg or from 1 mg to 25 mg.
  • Still more preferred is any one of the above aspects of the method, wherein the patient is a human and the second amount is from 1 mg to 15 mg; still more preferred is wherein the patient is a human and the second amount is from 1 mg to 8 mg. Still more preferred is any one of the above aspects of the method, wherein the patient is a human and the second amount is 2 mg, 4 mg, or 8 mg; still more preferred is wherein the patient is a human and the second amount is 2 mg, 4 mg, or 8 mg, which is administered once per day, or 1 mg, 2 mg, or 4 mg, which is administered twice per day.
  • N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide is polymorph Form IV of N-[(R)-2,3-dihydroxy- propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.
  • Figures 1 to 4 graphically display changes in paw edema versus experiment day from a mouse collagen-induced arthritis experiment with Compound (I) alone, methotrexate alone, combinations of Compound (I) and methotrexate, and vehicle and normal controls, and recite AUC % lnh of paw edema.
  • Figures 5 to 8 graphically display changes in average total clinical score versus experiment day from the mouse collagen-induced arthritis experiment with Compound (I) alone,. methotrexate alone, combinations of Compound (I) and - - methotrexate, and vehicle and normal controls, and recite AUC % lnh of a decrease in average total clinical score.
  • Figures 9 to 12 graphically display changes in body weight for each treatment and control group of animals from the mouse collagen-induced arthritis experiment.
  • This compound is also known by the names: methotrexate; (S)-2- ⁇ 4-[(2,4-diamino- pteridin-6-ylmethyl)-methyl-amino]-benzoylamino ⁇ -pentanedioic acid; N-[p-[[(2,4- diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-(+)-glutamic acid; (+)- amethopterin; L-amethopterin; amethopterin; amethopterine; 4-amino-10-methylfolic acid; 4-amino-N 10 -methylfolic acid; 4-amino-N 10 -methylpteroylglutamic acid; antifolan; CL-14377; EMT-25299; emtexate; L-methotrexate; ledertrexate; MTX; metatrexan; methotrexat-ebewe; methylaminopterin
  • Compound (I) may be amorphous or crystalline. Crystalline forms of Compound (I) include polymorph Forms I, II, and IV. Compound (I) is a highly specific, non-ATP-competitive inhibitor of the enzymes MEK1 and MEK2.
  • AUC - area under the plasma drug concentration-time curve AUC ( o- 24) - area under the plasma drug concentration-time curve from 0 to 24 hours post dose AUC ( o- t i ast) - area under the plasma drug concentration-time curve from Time
  • ECG electrocardiogram
  • EDTA ethylenediaminetetraacetic acid FDA - United States Food and Drug Administration
  • HERG human ether-a-go-go related gene
  • Another aspect of the present invention is a combination, consisting essentially of N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid, or a pharmaceutically acceptable salt thereof, or a mixture thereof, and N-[(R)- 2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.
  • Preferred is the combination consisting essentially of N-[4-[[(2,4-diamino-6- pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid and N-[(R)-2,3-dihydroxy- propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.
  • combination consisting essentially of sodium N-[4-[[(2,4-diamino-6- pteridinyl)methyl]methylamino]benzoyl]-L-glutamate and N-[(R)-2,3-dihydroxy- propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.
  • N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro- 2-(2-fluoro-4-iodo-phenylamino)-benzamide is polymorph Form IV of N-[(R)-2,3- dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.
  • a “combination” includes admixed components, packages containing each component, and combinations prepared in vivo in a patient by administration of the combination's components to the patient.
  • Preferred is a combination of admixed components.
  • the phrase "consisting essentially of,” when referring to a combination of the present invention, means the combination may contain, in addition to the methotrexate, or a pharmaceutically acceptable salt thereof, or a mixture thereof, and the Compound (I), pharmacologically-inactive components, but the combination may not contain additional components that are alleged in the prior art to have pharmacological activity.
  • the phrase "or a mixture thereof” means the combination of the present invention optionally may consist essentially of Compound (I) and: (i) a mixture of methotrexate and one or more salts thereof, preferably no more than two salts thereof; or (ii) a mixture of two or more salts of methotrexate, preferably no more than two salts thereof.
  • the invention combination includes heterogeneous and homogenous mixtures of its components. The combination includes mixtures of amorphous forms, crystalline forms, and an amorphous form and a crystalline form of Compound (I).
  • treating means prophylactic treatment, i.e., delaying the onset of a disease, or palliative treatment, which palliative treatment alleviates, inhibits the progress of, prevents further progress of, or reverses progression of, in part or in whole, any one or more pathologies or symptoms of the disease being treated.
  • palliative treatment is preferred.
  • the effect of clinical treatment of rheumatoid arthritis in human patients may be assessed by a physician of ordinary skill in-the art using a primary outcome measure for regulatory approval of anti-rheumatoid arthritis drugs.
  • ACR-20 The American College of Rheumatology (ACR)/World Health Organization (WHO) responder index, ACR-20, standard is a 20% improvement in multiple measures, expressed as a composite score; see, for example, Felson, David T., et al., ACR Preliminary Definition of Improvement in Rheumatoid Arthritis, Arthritis &
  • Other standards include ACR-50% and ACR-70%.
  • the physician may diagnose rheumatoid arthritis in a human patient upon clinical evaluation of the patient's signs and symptoms using ACR-20 criteria or the like.
  • Clinical signs and symptoms of rheumatoid arthritis include pain, swelling, stiffness, and loss of function in a joint such as knuckle, knee, and the like.
  • the ACR-20% standard is the preferred primary outcome measure.
  • a veterinarian of ordinary skill in the art may diagnose rheumatoid arthritis in non- human patients.
  • a human patient in need of prophylactic treatment of rheumatoid arthritis may be identified by the physician as someone having a family history of, a genetic marker for developing, or premature clinical signs and symptoms of rheumatoid arthritis.
  • the veterinarian may identify non-human patients in need of prophylactic treatment of rheumatoid arthritis similarly.
  • the term "administering," as applied to the combination of the present invention includes simultaneous or substantially simultaneous administration of different pharmacologically-active components, and sequential administration, wherein a pharmacologically-active component is administered, and then, after a waiting period, another pharmacologically-active compound is administered. The waiting period may be readily determined by the physician or veterinarian.
  • the pharmaceutically-active components of the combination may be administered in any order. For example, a first amount of one pharmaceutically-active component may be administered before, at the same time as, or after administration of a second amount of another pharmaceutically-active component.
  • first and second when referring to an amount, a pharmaceutical composition, etc. is done herein for convenience and the terms do not refer to an order or sequence of using the amounts, pharmaceutical compositions, etc. in a method of the present invention.
  • a first and a second amount may be the same or different.
  • patient means a mammal and includes humans, companion animals such as cats, dogs, and the like, primates such as monkeys, chimpanzees, and the like, livestock animals such as horses, cows, pigs, sheep, and the like, and laboratory animals such as cats, dogs, rats, mice, guinea pigs, hamsters, rabbits, monkeys, pigs, and the like.
  • a preferred patient is a human.
  • the patient is a non-human mammal.
  • Preferred non-human mammals are cats, dogs, and horses. More preferred non-human mammals are cats and dogs.
  • a “patient in need of rheumatoid arthritis treatment” means a patient who is in need of prophylactic treatment of rheumatoid arthritis, i.e., in need of delaying the onset of rheumatoid arthritis, or in need of palliative treatment of rheumatoid arthritis, which palliative treatment alleviates, inhibits the progress of, prevents further progress of, or reverses progression of, in part or in whole, any one or more pathologies or symptoms of rheumatoid arthritis in the patient.
  • a “therapeutically effective amount of a combination” is an amount of the combination that is effective for treating the disease being treated.
  • a therapeutically effective amount for the treatment of rheumatoid arthritis includes an amount sufficient to effect, even temporarily, an improvement in one of a patient's clinical signs or symptoms or ACR-20 evaluation. This amount may comprise an amount of an individual component of the combination that is less than the amount required for monotherapeutic treatment of the disease with the individual component.
  • Methotrexate is capable of forming pharmaceutically acceptable salts, including acid addition and base addition salts. All pharmaceutically acceptable salt forms of methotrexate are included within the scope of the present invention. Scientific literature describes types of pharmaceutically acceptable salts and their general preparations; see, for example, Berge S.M. et al., "Pharmaceutical Salts," J. of Pharma. Sci., 1977;66:1.
  • compositions derived from methotrexate include salts derived from inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, hydrofluoric, phosphorous, and the like, as well salts derived from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl- substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc.
  • inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, hydrofluoric, phosphorous, and the like
  • organic acids such as aliphatic mono- and dicarboxylic acids, phenyl- substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc.
  • Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, malate, tartrate,- methanesulfonate, and the like.
  • methotrexate salts with amino acids such as arginate and the like and gluconate, galacturonate.
  • An acid addition salt of methotrexate may be prepared by contacting methotrexate with a sufficientamount of a desired acid to produce-the saltin a conventional manner.
  • the acid addition salt may be converted back to methotrexate by contacting the acid addition salt with a base, and isolating methotrexate in a conventional manner.
  • Pharmaceutically acceptable base addition salts of methotrexate include sodium cation (Na + ), potassium cation (K + ), magnesium cation (Mg ⁇ + ), calcium cation (Ca ⁇ + ), and the like salts and salts with suitable amines such as N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine.
  • suitable amines such as N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine.
  • Monosodium and disodium salts, and the like of methotrexate, and divalent metal cation salts of methotrexate that have 1 :1 or 1 :2 ratios of the divalent metal cation to methotrexate, are contemplated.
  • a base addition salt may be prepared in a conventional manner by contacting methotrexate with a sufficient amount of a desired base such as a metal cation hydroxide, e.g., a hydroxide of an alkali or alkaline earth metal cation, to give a metal cation salt, or the amine, especially an organic amine, to give an amine salt.
  • a desired base such as a metal cation hydroxide, e.g., a hydroxide of an alkali or alkaline earth metal cation, to give a metal cation salt, or the amine, especially an organic amine, to give an amine salt.
  • a base addition salt of methotrexate may be converted back to methotrexate by contacting the base addition salt with an acid, and isolating methotrexate in a conventional manner.
  • Preferred is methotrexate. More preferred is methotrexate sodium.
  • Methotrexate, or a pharmaceutically acceptable salt thereof, or a mixture thereof, and Compound (1) can exist in unsolvated forms as well as solvated forms, including hydrated forms and partially solvated forms (i.e., forms wherein the molar ratio of compound to solvent is not 1 :1 , i.e., is greater than or less than 1 ).
  • Preferred solvates are those wherein the molar ratio of compound to solvent is greater than or equal to 1.
  • Unsolvated and hydrated forms are preferred.
  • the solvated forms and unsolvated forms are all encompassed within the scope of, and useful in, the present invention.
  • the present invention includes the use of isotopically-labeled methotrexate, or a pharmaceutically acceptable salt thereof, or a mixture thereof, and of isotopically- labeled Compound (1), which are identical to "unlabeled" methotrexate, a salt thereof, or Compound (I) recited above, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (i.e., different from the naturally abundant atomic mass or mass number).
  • contemplated isotopes include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 0, 17 O, 31 P, 32 P, 35 S, 18 F and 36 CI, respectively.
  • the isotopically-labeled compounds for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability.
  • An isotopically-labeled compound can generally be prepared by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent in a conventional method of preparing the compound.
  • compositions of the present invention include homogeneous and heterogeneous mixtures.
  • the methods of the present invention may employ any dosage form of methotrexate, or a pharmaceutically acceptable salt thereof, or a mixture thereof, or Compound (I), or both.
  • Preferred is an oral dosage form of Compound (I); more preferred is a tablet or capsule oral dosage form.
  • Preferred is an oral or injectable dosage form of methotrexate, or a pharmaceutically acceptable salt thereof, or a mixture thereof; more preferred is an oral dosage form; and still more preferred is a tablet or capsule oral dosage form.
  • Pharmaceutically acceptable excipients include pharmaceutically acceptable diluents, carriers, stabilizers, and other components such as capsule shells, for example gelatin capsule shells.
  • pharmaceutically acceptable excipients include sugars such as lactose and sucrose; starches such as corn starch and potato starch; cellulose derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, and cellulose acetate phthalate; gelatin; talc; stearic acid; magnesium stearate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and oil of theobroma; propylene glycol, glycerin; sorbitol; polyethylene glycol; water; agar; alginic acid; isotonic saline, and phosphate buffer solutions; as well as other compatible substances normally used in pharmaceutical formulations.
  • compositions to be employed in the present invention may also contain other components such as coloring agents, flavoring agents, and/or preservatives. These other components, if present, are usually used in relatively small amounts.
  • Suitable pharmaceutically acceptable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • Another aspect of the present invention is a package, comprising (i) a first pharmaceutical composition containing methotrexate, or a pharmaceutically acceptable salt thereof, or a mixture thereof, and a first pharmaceutically acceptable excipient, (ii) a second pharmaceutical composition containing Compound (I) and a second pharmaceutically acceptable excipient, and (iii) instructions for using-the first and second pharmaceutical compositions to treat rheumatoid arthritis in a patient in need of rheumatoid arthritis treatment, wherein the first pharmaceutical composition and the second pharmaceutical composition do not contain any other pharmacologically-active component.
  • the first pharmaceutically acceptable excipient and the second pharmaceutically acceptable excipient may be the same or different, and the first pharmaceutical composition and the second pharmaceutical composition may be suitable for routes of administration that are the same or different.
  • Another aspect of the present invention is a pharmaceutical composition, comprising methotrexate, or a pharmaceutically acceptable salt thereof, or a mixture thereof, Compound (I), and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition does not contain any other pharmacologically-active component.
  • Another aspect of the present invention is a method of treating rheumatoid arthritis in a patient, the method comprising administering to a patient in need of rheumatoid arthritis treatment a therapeutically effective amount of a pharmaceutical composition, comprising a first amount of methotrexate, or a pharmaceutically acceptable salt thereof, or a mixture thereof, a second amount of Compound (I), and a pharmaceutically acceptable excipient.
  • a preferred aspect of the present invention is the method of treating rheumatoid arthritis, wherein the methotrexate, or a pharmaceutically acceptable salt thereof, or a mixture thereof, and Compound (I) are as described herein in any one of the preferred aspects of the combination or method of the present invention.
  • Another aspect of the present invention is a method of treating rheumatoid arthritis in a patient, the method comprising separately administering to a patient in need of rheumatoid arthritis treatment a first pharmaceutical composition, comprising a first pharmaceutically acceptable excipient and a first therapeutically effective amount of methotrexate, or a pharmaceutically acceptable salt thereof, or a mixture thereof, and a second pharmaceutical composition, comprising a second pharmaceutically acceptable excipient and a second therapeutically effective amount of Compound (I).
  • the first pharmaceutically acceptable excipient and the second pharmaceutically acceptable excipient may be the same or different, and the first pharmaceutical composition and the second pharmaceutical composition may be administered to the patient at the same time or atdifferent times and by the same or different routes.
  • a preferred aspect of the present invention is the method of treating rheumatoid arthritis, wherein the methotrexate, or a pharmaceutically acceptable salt thereof, or a mixture thereof, and Compound (I) are as described herein in any one of tha preferred aspects of the combination or method of the - - present invention.
  • Another aspect of the present invention is a use of a combination consisting essentially of a first amount of N-[4-[[(2,4-diamino-6- pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid, or a pharmaceutically acceptable salt thereof, or a mixture thereof, and a second amount of N-[(R)-2,3- dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide in the manufacture of a medicament for treating rheumatoid arthritis in a patient.
  • a preferred use is wherein the patient is a human.
  • a therapeutically effective amount of the methotrexate sodium in a method of treating rheumatoid arthritis in a human patient according to a method of the present invention is typically from 1 mg to 30 mg in a human patient of average weight.
  • a preferred amount of methotrexate sodium for such treatment is 2.5 mg, 5.0 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, or 30 mg; also preferred is from 1 mg to 25 mg or from 1 mg to 20 mg.
  • a preferred therapeutically effective amount of methotrexate, or a non- sodium pharmaceutically acceptable salt thereof, or a mixture thereof, for treating human rheumatoid arthritis is an amount that will provide 0.0050 mol, 0.010 mol, 0.015 mol, 0.020 mol, 0.030 mol, 0.040 mol, or 0.060 mol of methotrexate, or the salt thereof, or the mixture thereof.
  • Such therapeutically effective amounts are preferably for weekly administration.
  • the weekly amounts may be divided and administered in portions throughout a seven day period. For example, a 17.5 mg per week dosage regimen may be divided into seven 2.5 mg dosages, which are administered daily for the week. Divided weekly amounts may further be subdivided for administration of sub-portions throughout any 24-hour period.
  • a weekly 15 mg dosage may be divided into two 7.5 mg portions for administration 3 days apart, and each 7.5 mg portion may be subdivided into three 2.5 mg portions for administration every 12 hours such that each 7.5 mg portion is administered within its own 24 hour period, which 24 hour periods are three days apart.
  • Drug holidays from methotrexate are included within the present invention.
  • a starting weekly-administered therapeutically effective amount of the methotrexate sodium is from 0.1 mg/kg to 1 mg/kg.
  • a veterinarian may optionally increase the amount of methotrexate sodium to find an optimal amount for the particular non- human patient being treated, which optimal amount may be up to 10 mg/kg/week.
  • the molar equivalent starting therapeutically effective amount of methotrexate, or another pharmaceutically acceptable salt thereof may optionally be used by the veterinarian in treating non-human patients.
  • a therapeutically effective amount of Compound (I) in a method of treating rheumatoid arthritis in a human patient according to a method of the present invention is-typically from 1 mg to 30 mg.
  • Compound (I) is from 1 mg to 20 mg, from 1 mg to 15 mg, or from 1 mg to 8 mg.
  • a more preferred therapeutically effective amount of Compound (I) is 2 mg, 4 mg, or 8 mg.
  • Such therapeutically effective amounts are preferably for daily administration.
  • the daily amounts may be divided and administered in portions throughout a 24-hour period.
  • Preferred is BID administration; more preferred is QD administration, although more or less frequent administration is within the scope of the present invention.
  • Drug holidays from Compound (I) are included within the present invention.
  • the dosing regimen for Compound (I) may be BID dosing for 21 days, followed by a 7 day drug holiday, to give a 28-day regimen that can be repeated for as long as a physician determines to be appropriate.
  • Compound (I) can be administered continuously without interruption until treatment is discontinued.
  • Compound (I) can be administered to a fasted patient (for example, no food or beverage within 2 hours before and after administration) or, preferably, to a non- fasted (i.e., with food) patient.
  • Administration of a therapeutically effective amount of Compound (I) once per day refers to QD dosing
  • administration of a therapeutically effective amount of Compound (I) twice per day refers to BID dosing.
  • a starting therapeutically effective amount of Compound (I) is from 0.01 mg/kg to 0.1 mg/kg.
  • a veterinarian may optionally increase the amount of Compound (I) to find an optimal amount for the particular non-human patient being treated, which optimal amount may be up to 1 mg/kg/day.
  • the dosing regimen may be BID dosing of Compound (I) and twice weekly dosing of methotrexate sodium for 21 days, followed by a 7 day drug holiday from both Compound (I) and methotrexate sodium, to give a 28-day regimen that can be repeated for as long as a physician determines to be appropriate.
  • a number of factors will generally be considered by a physician or veterinarian in view of his or her experience.
  • the administered dose may fall within the ranges recited herein, or may be either below or above those ranges. Determination of a proper dose for a particular situation is routine and within - the ordinary skill of the physician or- veterinarian. Generally, treatment may-be initiated using smaller dosages of a pharmacologically-active component that are less than optimal for a particular patient. Thereafter, the dosage can be increased by small increments until an acceptable effect under the circumstance is reached.
  • Methotrexate, or a pharmaceutically acceptable salt thereof, or a mixture thereof, and Compound (I) may be formulated in bulk form or dosage unit form.
  • the pharmaceutical compositions of the present invention are in unit dosage form.
  • a pharmaceutical preparation is subdivided into unit doses containing an appropriate quantity of the pharmacologically-active component(s).
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparations such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • a unit dosage formulation may contain less than a therapeutically effective amount of a pharmacologically-active component for the disease or disorder being treated, and thus require administration of more than one unit dosage to the patient to treat a disease.
  • dosage unit forms are tablets, capsules, pills, powders, aqueous and nonaqueous oral solutions and suspensions, and parenteral solutions packaged in containers containing either one or some larger number of dosage units and capable of being subdivided into individual doses.
  • the total percentage of the pharmacologically-active components can be varied within wide limits, but for practical purposes it is preferably at least 5% by weight in a solid composition and at least 2% by weight in a primary liquid composition.
  • the most satisfactory compositions are those in which a much higher proportion of the pharmacologically-active components is present, for example, up to about 95% by weight.
  • Different routes of administration may require different amounts, dosages, or percentages.
  • a pharmaceutical composition of the present invention that is suitable for oral administration includes a tablet, capsule, powder, pill, lozenge, aqueous suspension or solution, melt formulation, and the like; preferred is a tablet or capsule.
  • the pharmaceutical composition includes the formulation of the pharmacologically-active component(s) with encapsulating material such as a capsule shell, providing a capsule in which the pharmacologically-active component(s), with or without other carriers, is surrounded by the capsule shell. Solid form preparations are preferred.
  • a pharmaceutical composition that is suitable for administration by injection includes an aqueous solution, a lyophilized powder capable of being dissolved in sterile water or saline, and the like.
  • a preferred therapeutic composition for dogs comprises an ingestible liquid peroral dosage form selected from the group consisting of a solution, suspension, emulsion, inverse emulsion, elixir, extract, tincture and concentrate, optionally to be added to the food or drinking water of the dog being treated.
  • a concentrate liquid form may be formulated for dissolution in a given amount of water, from which solution an aliquot amount may be withdrawn for administration directly to the dog or addition to the dog's food or drinking water.
  • Controlled-release forms are particularly useful when formulating an invention combination having pharmacologically-active components with different half-lives. Controlled-release forms can be prepared that have different release times for each of the pharmacologically-active components, which forms allow relatively uniform dosing.
  • compositions also include a medicated feed dosage form in which the pharmacologically-active components are present together in a feed composition.
  • Solid form preparations such as powders, tablets, pills, capsules, cachets, suppositories, lozenges, and dispersible granules can be formulated with a solid carrier.
  • a solid carrier can be one or more substances that may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the pharmacologically-active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • the carrier is a finely divided solid that is in a mixture with the finely divided pharmacologically-active component.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the pharmacologically-active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided pharmacologically-active component in water with viscous material, such as natural-or-synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
  • viscous material such as natural-or-synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
  • Liquid form preparations include solutions, suspensions, and emulsions, for example, water, saline, or water propylene glycol solutions.
  • liquid preparations can be formulated using solvents such as saline and aqueous polyethylene glycol solution. Powders suitable for intravenous administration or administration by injection may be lyophilized.
  • solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for injection or oral administration.
  • Such liquid forms include solutions, suspensions, and emulsions.
  • These preparations may contain, in addition to the pharmacologically-active component(s), colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • Methotrexate, or a pharmaceutically acceptable salt thereof, or a mixture thereof, and Compound (1) can be administered by different routes such as oral ingestion of a tablet, capsule, powder, solution and the like or by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Continuous administration such as by intra-arterial infusion from a surgically implanted pump is also contemplated.
  • Preferred routes of administration of methotrexate, or a pharmaceutically acceptable salt thereof, or a mixture thereof, are oral or by injection; more preferred is oral.
  • a preferred route of administration of Compound (I) is oral. However, another route of administration of the compounds may be preferred depending upon the particular condition being treated. Topical administration by transdermal patch may be preferred where, for example, it is desirable to effect sustained systemic dosing.
  • Step A To a solution of 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid (39.3 g, 100.0 mmol) in dry tetrahydrof uran (500 mL, 0.2 M), under nitrogen atmosphere, was added ('f? / )-O-(2,2-dimethyl-[1 ,3]dioxolan-4-ylmethyl)-hydroxylamine (14.7 g, 100.0 mmol), followed by ⁇ /-methylmorpholine (27.5 mL, 0.25 mole). The orange-colored solution was cooled with an ice-water bath.
  • Diphenylphosphinic chloride (22.9 mL, 0.12 mol) was added dropwise. Some solid formed. The mixture was warmed to ambient temperature and stirred for 18 hours. Water was added to quench the reaction, and the tetrahydrofuran was rotary evaporated in vacuo. The remaining oil was dissolved in ethyl acetate (500 mL) and washed with a mixture of saturated brine and saturated sodium bicarbonate (1 :1) two times.
  • Step B N-((R)-2,2-Dimethyl-[1 ,3]dioxolan-4-ylmethoxy)-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide (22.3 g, 42.7 mmol) was suspended in methanol (223 mL, 10 mL/g), and a solution of pTsOH-H 2 O (4.1 g, 21.35 mmol) in water (22.3 mL) was added. The mixture was stirred at ambient temperature for 18 hours, during which all solids dissolved to give a colorless, clear solution. The solution was concentrated and extracted with ethyl acetate (2 x 300 mL).
  • N-methyl morpholine (0.70 mL, 6.375 mmol) was added and the reaction stirred an additional 20 minutes.
  • (fl>O-(2,2-dimethyl-[1 ,3]dioxolan-4-ylmethyl)- hydroxylamine (0.748 g, 5.1 mmol) was added and the reaction stirred for 1 hour, at which point ⁇ /-methylmorpholine (0.7 ml_, 6.37 mmol) was added.
  • the mixture was warmed to ambient temperature and stirred for 12 hours.
  • the reaction was concentrated in vacuo and then diluted with EtOAc. The organic layer was washed with saturated NaHCO 3 (2 times), brine (1 time), dried over Na 2 SO 4 , filtered and concentrated.
  • Step B N-((R)-2,2-Dimethyl-[1 ,3]dioxolan-4-ylmethoxy)-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benzamide (0.210 g, 0.40 mmol) was suspended in 10:1 methanol/H 2 O and pTsOH ⁇ 2 O (0.008 g, 0.04 mmol) was added. The mixture was stirred at ambient temperature for 18 hours, during which all solids dissolved to give a colorless, clear solution. The solution was diluted with EtOAc. The organic solution was washed with sodium bicarbonate (2 times), brine (1 time) and dried over Na 2 SO 4 .
  • the remaining top layer was concentrated by vacuum distillation, and then diluted with 15 L of toluene and 2 L of ethanol. The mixture was warmed to 35 - 45°C and diluted with 20 L of warm water, then cooled to 0 - 5°C. The product was collected by filtration and washed with 2 L of toluene. The product was recrystallized by dissolving in 12 L of toluene and 2 L of ethanol (50° ⁇ 5 C), adding 10 L of water and cooling to 0 - 5 0 C.
  • Table 1 lists the X-ray powder diffraction pattern for polymorph Form IV of Compound (I), expressed in terms of the 2-theta ("2 ⁇ "), d-spacings or d(A), and relative intensities by peak area with a relative intensity of >10% measured on a Rigaku Ultima + diffractometer with CuK ⁇ radiation.
  • Table 1 lists the X-ray powder diffraction pattern for polymorph Form IV of Compound (I), expressed in terms of the 2-theta ("2 ⁇ "), d-spacings or d(A), and relative intensities by peak area with a relative intensity of >10% measured on a Rigaku Ultima + diffractometer with CuK ⁇ radiation.
  • Compound (I) was shown to be a selective inhibitor of MEK1 and MEK2 in vitro.
  • Compound (I) was also tested in a "cascade" assay in which activated B-Raf, unactivated MEK1 , and ERK1 were present. In this cascade assay, activated B-Raf phosphorylates and activates MEK1 , and activated MEK1 in turn phosphorylates ERK1.
  • the readout is phosphorylation of ERK1.
  • Inhibitors that bind to either the unactivated or the activated form of MEK1 can inhibit this assay.
  • the Ki app for Compound (I) was 0.90+0.09 nM in the cascade assay.
  • the kinase specificity of Compound (I) was evaluated against a panel of 27 kinase enzymes. This panel, which was comprised of tyrosine kinases as well as a multitude of serine/threonine kinases, was refractory to inhibition by a 10 //M concentration of Compound (I). Therefore, Compound (I) appears to be a highly specific inhibitor of MEK1 and MEK2 versus other kinases.
  • Example 2 Genetic Toxicology and Safety Pharmacology Studies of Compound (I) Compound (I) has been examined in various genetic toxicology and safety pharmacology (cardiovascular, central nervous system (CNS), and pulmonary) studies. General toxicology studies have been conducted in rats, dogs, and monkeys. Most studjes used QD oral dosing by gavage, although a limited number of studies used IV administration. Definitive toxicology studies were conducted in rats and dogs, in which Compound (I) was administered orally by gavage QD for 1 -month, followed by a 1 -month reversal period.
  • CNS central nervous system
  • Gastrointestinal tract toxicity is dose-limiting in dogs and monkeys and is anticipated to be the dose-limiting toxicity of Compound (I) in the human patients.
  • protocol incorporated a plan for intensive monitoring focused on detecting early abnormalities in calcium and phosphorus metabolism, and no significant abnormalities in serum phosphorus and calcium regulation were seen.
  • the primary Compound (I) toxicities in preclinical studies were to the gastrointestinal tract (rat, dog, and monkey), skin (rat, dog, and monkey), liver (rat), bone (rat), and systemic mineralization (rat only). Injury to the mucosa of the gastrointestinal tract was the dose-limiting toxicity in non-rodents. Results of the safety pharmacology studies were generally unremarkable.
  • Compound (I) indicated a potential for clastogenicity in the in vivo micronucleus study in rats.
  • Grade 1-2 transient and reversible visual effects including blurred vision and halos were seen without a discernable pattern relevant to dose level or patient characteristics. These typically were less severe later in a drug cycle, during intercycle drug holidays, and during subsequent cycles.
  • One patient developed unilateral visual decrements, and was found to have ipsilateral optic disc edema and intraretina] hemorrhages in one eye, whereas opthamologic exam of the contralateral eye revealed no abnormalities.
  • Grade 1-2 dependent and facial edema was seen intermittently with all dose levels.
  • Grade 1-2 diarrhea was seen; the diarrhea responded well to loperamide hydrochloride treatment.
  • a cohort of 6 additional patients was entered onto a cohort of 20 mg BID continuous dosing in two 28 day cycles (56 days total).
  • one patient developed a DLT of grade 3 acneiform rash and four patients demonstrated upwards trends in liver function tests during the second cycle.
  • 20 mg BID was considered above the MTD in a continuous dosing regimen and subsequent patients were treated at 15 mg BID continuous dosing.
  • Tumor tissue was assessed by immunohistochemistry (IHC) for pERK at baseline (BL) and Day 15 of Cycle 1 as described in Experiment 4 and for the amount of Ki67 as described below in Experiment 5.
  • IHC immunohistochemistry
  • Pharmacokinetic (PK) samples were obtained on Days 1 and 21 in all patients and also on Day 1 of Cycle 2 in patients participating in a 2-way crossover food effect component. Due to elevated serum phosphorus with corresponding soft tissue mineralization observed in rats, serum calcium, phosphorous and (Ca x P) product were monitored closely.
  • Grade 1-2 transient and reversible- visual effects including blurred vision and halos have been reported. These typically were less severe later in a drug cycle, during intercycle drug holidays, and during subsequent cycles. Grade 1-2 dependent and facial edema was seen intermittently with all dose levels.
  • the MAD was 30 mg BID, and the MTD when dosing 21 days of a 28-day cycle was determined to be 20 mg BID, secondary to 1/6 cases of DLT Grade 3 acneiform skin rash and 2/6 cases of DLT syncope (Grade 3 by CTC AE 3.0) at 30 mg BID on 21 day dosing in 28-day cycles. Cohorts of 6 patients each were subsequently treated at 20 mg bid and 15 mg bid with dosing continuously over 28- day cycles. A DLT was seen in one patient in each cohort (grade 3 acneiform skin rash).
  • ERK protein also known as MAP kinase, or MAPK
  • MAPK MAP kinase
  • the phosphorylation status of ERK can be assessed through antibody-based detection methods, utilizing phosphorylation site- specific antibodies.
  • the biopsies were collected from tumor lesions amenable to either excisional or core needle biopsy procedures; the tissue specimens were immediately placed into 10% neutral-buffered formalin solution for fixation (nominally 6-8 hours, but no more than 24 hours in formalin). The fixed tissues were then transferred to 70% ethanol solution and submitted to the histopathology assay lab for immunohistochemistry (IHC) analysis of both p-ERK and the proliferation marker Ki67 (Experiment 5). The biopsy tissues were paraffin- embedded following standard tissue processing. The antibody used for detection of p-ERK was the mouse monoclonal anti-MAP kinase (activated) antibody, manufactured by Sigma-Aldrich Co. (catalog number: M8159).
  • This antibody is reacts specifically with the di-phosphorylated form of MAPK (both the ERK-1 and ERK-2 forms).
  • Tissue sections prepared from the paraffin blocks were pretreated with Heat-induced Epitope Retrieval conditions (3 minutes at 120 0 C) prior to the detection procedure.
  • a DAKO Envision plus kit was used for visualization of the antibody bound to sections, with DAB Chromogen as the chromogen.-
  • a Biogenex Autostainer system was used in the staining procedure (with hematoxylin counterstaining).
  • Staining intensity was grouped in categories from 0 to 3+, with 0 being little or no staining, and 3 being the most intense staining.
  • H-score The final score for each section was given in the form of an H-score, which was calculated as follows: 3 X (% of cells with 3+ staining) + 2 X (% of cells with 2+ staining) + 1 X (% of cells with 1+ staining). For each biopsy specimen, 2 sections were analyzed and the average of these was taken for the p- ERK H-score. In addition to H-scores, the total % of positive cells was also recorded. Comparison of pre-treatment biopsies to the post-treatment biopsy from the same patient was calculated based on H-scores using the following formula: the negative of ((pre-post)/pre) X 100; to give the percentage difference in p-ERK associated with treatment with Compound (I).
  • Experiment 5 lmmunohistochemical Analysis of Cell Proliferation Marker Ki67 in Paired Serial Biopsy Specimens from Human Cancer Patients Treated with Compound (I)
  • the same biopsy specimens as those analyzed for p-ERK staining described in Experiment 4 were also assessed for the amount of Ki67 detectable by immunohistochemistry.
  • the Ki67 marker is considered an indicator of cell proliferation and thus reduction in Ki67 staining levels may be correlated with anti- tumor activity of anticancer agents.
  • Tissue sections from the paraffin-embedded biopsy tissues were pretreated with Heat-induced Epitope Retrieval (in this case, microwaving for 3 minutes) prior to the Ki67 detection procedure.
  • the antibody used was the mouse monoclonal Ki67/MM1 manufactured by Novocastra Laboratories, Ltd. (catalog number: NCL-Ki67-MM1).
  • a Biogenex Supersensitive DAB/HRP detection kit was used for visualization of the antibody bound to sections, with DAB Chromogen as the chromogen.
  • a Biogenex Autostainer system was used in the staining procedure (with hematoxylin counterstaining). The extent of staining in individual sections was assessed by pathologist review, with scoring based on the relative staining color intensities in tumor cells in each section. Scoring of staining intensity was performed in same manner as for p-ERK assay, with H-scores generated for each section. For Ki67, only one section was assayed for each biopsy specimen. The percentage difference in Ki67 scores associated with Compound (I) was calculated in the same manner as for p-ERK.
  • a first-in-human Phase I/Phase Il trial employed an open-label, dose- escalating design where patients with various advanced solid tumors were treated orally with Compound (I) (QD or BID) for 21 or 28 days in 28-day cycles.
  • Pharmacokinetic data are presented for the first 38 subjects. Dose escalation was conducted from 1 mg QD, and 1 mg BID through 30 mg BID. Continuous dosing at 20 mg BID for 56 days was subsequently tested.
  • a liquid chromatographic method with tandem mass spectrometry detection was used to quantitate Compound (I), Compound (III), and Compound (II) in human plasma with EDTA as an anticoagulant.
  • Compound (I) and its stereoisomer Compound (III) along with the metabolite Compound (II) were isolated from EDTA- treated human plasma by liquid/liquid extraction. Plasma samples were stored at - 2O 0 C until analysis. Analysis is by LC/MS/MS in the negative ion mode using multiple reaction monitoring.
  • the range of quantitation for Compound (I), Compound (III), and Compound (II) was 0.100 to 100 ng/mL This assay required a 0.200 ml_ aliquot of plasma. Samples were extracted by using the following procedure. Sample Extraction:
  • Mobile Phase Mobile Phase A: 0.1% acetic acid in water, v/v
  • Mobile Phase B 90:10 acetonitrile/isopropanol, v/v 17:83 Mobile Phase A/Mobile Phase B Needle Flush Solvent: 300:300:400:1
  • PE Sciex Analyst software (Version 1.2) was used to measure peak areas.
  • Watson LIMS (Version 6.4.0.04, CPL #63) was used for data reduction. Samples are quantified by applying a 1 /(concentration) 2 weighted quadratic regression analysis.
  • Pharmacokinetic parameters were determined by the non-compartmental method using WINNONLIN Professional Edition (Version 4.1).
  • the liner trapezoidal method was used to calculate area under the concentration-time curve from 0 to 24 hours (AUCo- 24 ).
  • the maximum observed concentration (C max ) was obtained by inspection of the concentration data.
  • the time to reach the C max was the first time at which C max is observed and obtained by inspection of the data.
  • the pre-dose concentration (C trough ) was obtained by inspection of the concentration data.
  • the average concentration at steady state (C ss , avg ) was calculated from AUC 0 . 24 on Day 21 divided by the daily dosing interval (24 hours).
  • Preliminary plasma pharmacokinetic parameters of Compound (I) are presented in Table 2.
  • Compound (I) administered in the fasted state was absorbed rapidly, with peak plasma concentrations occurring within 1 to 2 hours after dosing.
  • both peak plasma levels (C max ) and area under the curve (AUC) were roughly dose proportional in a range of 1 mg QD or BID - 30 mg BID.
  • AUC of Compound (I) increased slightly with an accumulation ratio of 1.1-2.2.
  • the inter-subject variability in Compound (I) pharmacokinetics was evaluated in this subject population. The overall coefficients of.
  • Compound (I) was dosed as purified (R)-enantiomer.
  • the in vivo interconversion from (R)- (i.e., Compound (I)) to S-enantiomer (i.e., Compound (III)) was evaluated in twenty-four subjects across eight different dosing regimens.
  • the average (S)-to-(R) ratio for AUC on Day 21 of cycle 1 was low, 0.03 (CV 38%); this excludes two outlier subjects with ratios of 12 and 21% each from the 1 mg BID cohort.
  • the plasma pharmacokinetics of Compound (I) in cancer patients is characterized by rapid absorption, with peak concentrations occurring within 1 to 2 hours of dosing, generally dose-proportional changes in exposures, and an elimination half-life of 5 to 16 hours. Food appeared to reduce Compound (I) peak plasma concentrations, but the effect on AUC was variable. Plasma pharmacokinetics for the major circulation metabolite Compound (I) was characterized by a longer half-life and up to 120% higher plasma exposures than the parent.
  • Table 5 represents data for the Phase I/Phase Il study.
  • Table 5 Data for the Phase I/Phase Il Study in Human Cancer Patients
  • Example 1 In Vivo Treatment of Rheumatoid Arthritis and Protection from Death 5
  • bovine type Il collagen (University of Utah) was diluted with 0.01 N acetic acid to a concentration of 2 mg/mL, and the mixture was emulsified with an equal volume of Freund's complete adjuvant (Difco, Detroit, Michigan) supplemented with 1 mg/mL of Mycobacterium tuberculosis Hra37.
  • Age-matched (8
  • mice 15 to 12 weeks
  • Female DBA/1 mice (Harlan, UK) were immunized on Day 0 with 100 ⁇ l_ of emulsion (100 ⁇ g collagen) intradermal ⁇ at the base of the tail. Mice were weighed on Day 27. Oral dosing with methotrexate and Compound (I) began on Day 27 and continued through Day 41 or Day 42; methotrexate was administered on a schedule of three times per week, Mondays, Wednesdays, and Fridays, and Compound (I) was
  • mice 20 administered QD during the dosing period.
  • Vehicle control mice were administered vehicle (HPMC/Tween-80) only and normal control mice were not administered anything.
  • the mice were given 50 ⁇ g LPS (Sigma Aldrich, St Louis, Missouri) intraperitoneal ⁇ (IP) in 100 ⁇ L saline.
  • IP intraperitoneal ⁇
  • each limb of each animal using the following scale: (0) normal, (1) erythema (i.e., abnormal redness of skin) and edema (i.e., swelling due to abnormal collection of fluid), (2) joint distortion, or (3) joint ankylosis (i.e., stiffness or fixation of joint).
  • erythema i.e., abnormal redness of skin
  • edema i.e., swelling due to abnormal collection of fluid
  • joint distortion i.e., swelling due to abnormal collection of fluid
  • joint ankylosis i.e., stiffness or fixation of joint

Abstract

Cette invention concerne une méthode permettant de traiter la polyarthrite rhumatoïde au moyen d'une combinaison comprenant essentiellement du N-[4-[[(2,4-diamino-6- pteridinyl)methyl]methylamino]benzoyl]-L-acide glutamique, ou un sel pharmaceutiquement acceptable de celui-ci, et du N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, ainsi que des combinaisons et des compositions pharmaceutiques associées.
PCT/IB2006/002745 2005-10-07 2006-09-25 Combinaison therapeutique WO2007042885A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72454205P 2005-10-07 2005-10-07
US60/724,542 2005-10-07

Publications (2)

Publication Number Publication Date
WO2007042885A2 true WO2007042885A2 (fr) 2007-04-19
WO2007042885A3 WO2007042885A3 (fr) 2007-12-06

Family

ID=37943172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002745 WO2007042885A2 (fr) 2005-10-07 2006-09-25 Combinaison therapeutique

Country Status (3)

Country Link
JP (1) JP2007106762A (fr)
AR (1) AR055677A1 (fr)
WO (1) WO2007042885A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066358B1 (en) 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11571402B2 (en) 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2023223205A1 (fr) 2022-05-17 2023-11-23 Teva Pharmaceuticals International Gmbh Formes à l'état solide de mirdamétinib et leur procédé de préparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006213A2 (fr) * 2000-07-19 2002-01-24 Warner-Lambert Company Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
WO2005040098A1 (fr) * 2003-10-21 2005-05-06 Warner-Lambert Company Llc Forme polymorphe du n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006213A2 (fr) * 2000-07-19 2002-01-24 Warner-Lambert Company Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
WO2005040098A1 (fr) * 2003-10-21 2005-05-06 Warner-Lambert Company Llc Forme polymorphe du n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CRONSTEIN B N: "Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis" PHARMACOLOGICAL REVIEWS, WILLIAMS AND WILKINS INC., BALTIMORE, MD,, US, vol. 57, no. 2, June 2005 (2005-06), pages 163-172, XP002408704 ISSN: 0031-6997 *
HOEKSTRA M ET AL: "Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis" ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 62, no. 5, May 2003 (2003-05), pages 423-426, XP002410166 ISSN: 0003-4967 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066358B1 (en) 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11427534B1 (en) 2021-02-17 2022-08-30 Springworks Therapeutics, Inc. Solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof
US11453641B2 (en) 2021-02-17 2022-09-27 Warner-Lambert Company Llc Methods of treating neurofibromatosis with N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US11571402B2 (en) 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11884610B2 (en) 2021-02-17 2024-01-30 Springworks Therapeutics, Inc. Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2023223205A1 (fr) 2022-05-17 2023-11-23 Teva Pharmaceuticals International Gmbh Formes à l'état solide de mirdamétinib et leur procédé de préparation

Also Published As

Publication number Publication date
JP2007106762A (ja) 2007-04-26
WO2007042885A3 (fr) 2007-12-06
AR055677A1 (es) 2007-08-29

Similar Documents

Publication Publication Date Title
US10052322B2 (en) Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one
US20130142873A1 (en) Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
KR20220125803A (ko) Mek 억제제 및 이의 치료 용도
UA113491C2 (xx) Аморфна та кристалічна форма гемітартрату genz 112638 як інгібітор глюкозилкерамідсинтази
UA120353C2 (uk) Модулятори натрієвого каналу для лікування болю і діабету
CA2908815A1 (fr) Associations medicamenteuses pour traiter un cancer
WO2007042885A2 (fr) Combinaison therapeutique
WO2014160430A1 (fr) Petites molécules inhibitrices d'erk5 et de lrrk2
JP2019116491A (ja) １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンの固体形態、その組成物、及びそれらの使用方法
US9975898B2 (en) Solid forms of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-YL)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one as tor kinase inhibitors
EP3840752A1 (fr) Méthodes de traitement de la myélofibrose indépendantes du nombre de plaquettes
AU2014207347A1 (en) Isometheptene isomer
KR101504571B1 (ko) 디스펩시아 진단 검사약
BG63803B1 (bg) Фармацевтичен състав за профилактика и лечение надиабетични усложнения
RU2812929C1 (ru) Ингибиторы mek и их терапевтическое применение
TW202042804A (zh) 使用lta4h抑制劑治療化膿性汗腺炎之方法
US11963962B2 (en) Platelet count-agnostic methods of treating myelofibrosis
TW201930256A (zh) 多晶型及其用途
WO2023083288A1 (fr) TRAITEMENT DE TROUBLES HÉPATIQUES AVEC UN AGONISTE DE THR-β
RU2772693C1 (ru) Твердые дисперсии и фармацевтические композиции, включающие замещенный индан, и способы их приготовления и применения
US20230270737A1 (en) Therapeutic Agent for Mild Cognitive Impairment
WO2023220404A1 (fr) Traitement de stéatohépatite non-alcoolique
AU2022281056A1 (en) A plurality of tasquinimod particles and use thereof
WO2023010111A1 (fr) Biomarqueur et sélection de patient dans le traitement de la myélofibrose
NZ629877B (en) SOLID FORMS OF 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06808933

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06808933

Country of ref document: EP

Kind code of ref document: A2